ProQR Therapeutics (PRQR) Total Liabilities (2021 - 2025)

ProQR Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $84.8 million for Q4 2024.

  • For Q4 2024, Total Liabilities fell 18.28% year-over-year to $84.8 million; the TTM value through Dec 2024 reached $84.8 million, down 18.28%, while the annual FY2024 figure was $85.9 million, 17.67% down from the prior year.
  • Total Liabilities for Q4 2024 was $84.8 million at ProQR Therapeutics, down from $103.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $110.2 million in Q4 2021 and bottomed at $84.8 million in Q4 2024.
  • The 4-year median for Total Liabilities is $105.3 million (2022), against an average of $101.4 million.
  • The largest annual shift saw Total Liabilities decreased 2.75% in 2023 before it decreased 18.28% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $110.2 million in 2021, then dropped by 3.14% to $106.8 million in 2022, then decreased by 2.75% to $103.8 million in 2023, then fell by 18.28% to $84.8 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Total Liabilities are $84.8 million (Q4 2024), $103.8 million (Q4 2023), and $106.8 million (Q4 2022).